In recent years novel treatment options for metastatic castration-resistant prostate cancer (mCRPC) are expanding. Among them, abiraterone acetate, which selectively inhibits CYP17 in androgen synthesis pathway, is widely used. However, liver metastasis is one of the worst prognostic factors in mCRPC. There are few cases reports that abiraterone is successfully used for liver metastasis of mCRPC. We report a case of mCRPC patient with extensive liver metastasis, who showed a remarkable response to abiraterone acetate.
Introduction
Although prostate cancer has a good clinical course in general, the patient with visceral metastasis still shows poor prognosis. The one recommended treatment for mCRPC with visceral metastasis is chemotherapy with docetaxel.
There are few cases reporting abiraterone acetate is effective for liver metastasis of mCRPC. We report a case of mCRPC patient with aggressive liver metastasis, who showed dramatic responses to abiraterone acetate.
Case Report
A 62-year-old man with a PSA of 16.69 ng/ml was diagnosed as a prostate cancer in former hospital in March 2011. The pathology of biopsy specimen shows Gleason 8 (3+5) poorly differentiated prostate adenocarcinoma. A whole-body examination showed multiple bone metastasis including the 12th thoracic vertebra, sacral, left sacroiliac joint, and left shoulder blade, as well as left obturator lymph node metastasis. Androgen deprivation therapy (ADT) with gosereline acetate (10.8mg every 3 months) and bicalutamide (80 mg/day) was introduced. His PSA reached nadir at 0.75ng/ml in April 2012, and elevated thereafter. The anti-androgen replacement had no effect. He was recommended to receive chemotherapy with docetaxel, but he refused. In January 2013, he received radiation therapy for bone metastases and discontinued ADT. After radiation, PSA decreased temporally, but increased to 59.70 ng/ml in February 2014, when multiple liver metastases were found. In radiological improvement and PSA fall [5] . However, the improvement of liver metastasis is only limited, not a drastic improvement like our case.
Ilaria reported abiraterone acetate caused partial response of liver metastasis after chemo therapy with docetaxel in 65-year-old man [6] . After the treatment with abiraterone acetate (1000 mg/day), liver metastasis decreased its diameter from 3 cm to 1.8 cm.
In our case, abiraterone acetate produced sustained CR in mCRPC with aggressive liver metastasis before chemotherapy. A recent study reported that the number of prior regimens is a predictive factor of low response to abiraterone acetate [7] . Our case suggested that abiraterone acetate could be an initial treatment option of CRPC with liver metastasis. 
